Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07259421

Survey of Practices Regarding the Use of Taurolidine Lock Solutions in Patients With Insertion of a Peripherally Inserted Central Catheter (PICC) in a Vascular Access Unit

The primary objective of this study is to describe current practices regarding the administration of taurolidine lock solutions in relation to medical prescriptions for patients who have undergone peripherally inserted central catheter (PICC) implantation in the Vascular Access Unit as part of parenteral nutrition therapy. Our underlying hypothesis is that the use of taurolidine lock solutions may deviate from current recommendations, particularly with respect to administration procedures.

This study will allow us to characterize the use of taurolidine lock solutions in relation to medical prescriptions, identify potential deviations from recommended practices, and document any associated adverse events. It will also enable follow-up of PICC outcomes at 8 and 30 days after implantation in the Vascular Access Unit, whereas current follow-up is performed only at 8 days post-insertion.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Taurolidine Lock Solution Catheter-Related Infections Cross Infection Disease Attributes Hyperphagia Iatrogenic Disease Infections Pathologic Processes Pathological Conditions, Signs and Symptoms Signs and Symptoms Signs and Symptoms, Digestive

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient who has undergone PICC placement in the vascular access unit with an indication for parenteral nutrition supplementation.
  • Patient not opposed to participating in this research.

Exclusion criteria

  • Patient not speaking French
  • Patient under guardianship or conservatorship
  • Patient with major neurocognitive disorders
  • Patient with severe hearing impairment
  • Patient who do not have a telephone

Treatment and study plan

Primary outcomes

  1. To characterize, through an assessment of current practices, the administration of taurolidine lock solutions as prescribed for patients who have undergone PICC implantation in the Vascular Access Unit as part of parenteral nutrition therapy.

    Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit

    Proportion of patients with a prescription for a taurolidine lock solution who actually receive administrations of the prescribed lock solution (concordance between prescribed and administered product).

    Proportion of patients for whom lock solutions are administered in accordance with the manufacturer's instructions for use; compliant administration is defined as the nurse performing all recommended steps for applying the lock solution at the end of each parenteral nutrition infusion.

    Proportion of patients for whom lock solutions are withdrawn in accordance with the manufacturer's instructions for use (lock solutions aspirated before catheter use).

    Proportion of patients for whom lock solutions are disposed of in accordance with regulations for biological-hazard waste.

Secondary outcomes

  1. Describe nurses' perceptions of their own knowledge regarding the use of taurolidine lock solutions.

    Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.

    Quantify, using a self-assigned score, nurses' level of knowledge concerning taurolidine lock solutions.

    Proportion of nurses aware of the various properties of lock solutions according to the references available on the market.

  2. Describe the medical care provided by home service providers for patients receiving a PICC placement for parenteral nutrition supplementation.

    Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.

    Nature and number of service providers working with patients at home.

  3. Describe the supply chain for taurolidine lock solutions.

    Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.

    Nature and proportions of procurement methods for taurolidine lock solutions for patients at home.

  4. Describe the elements related to PICC placement.

    Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.

    Nature and proportions of elements related to PICC placement: number of lumens, vein of insertion, side of insertion, duration of placement, and role of the inserter (nurse anesthetists or physician).

  5. Characterize the functional status of the PICC over time.

    Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.

    Proportion of PICC in place and functional at 8 and 30 days post-insertion, defined as not requiring premature removal and allowing infusion and blood sampling.

  6. Describe complications related to PICC placement.

    Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.

    Nature and proportions of complications related to the PICC occurring within 8 and 30 days post-insertion.

  7. Describe the causes of premature PICC removal.

    Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.

    Nature and proportions of causes for premature PICC-line removal within 8 and 30 days post-insertion.

  8. Describe adverse events related to the use of taurolidine lock solutions.

    Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.

    Nature and proportion of adverse events potentially related to the use of a taurolidine lock solution, as reported by patients or healthcare providers.

  9. Describe the difficulties encountered by healthcare professionals when using taurolidine lock solutions.

    Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.

    Nature and proportion of difficulties encountered by home-care nurses when using taurolidine lock solutions.

  10. Describe the information sources used by healthcare professionals regarding taurolidine lock solutions.

    Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.

    Nature and proportion of information sources consulted by nurses in the event of problems related to the use of a taurolidine lock solution or to the use of the PICC.

  11. Characterize the use of device vigilance in the event of adverse events related to taurolidine lock solutions.

    Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.

    Proportion of nurses who would report to device vigilance any adverse events related to the use of a taurolidine lock solution or to the use of the PICC, should such events occur.

Study contacts

Contact information is provided by the study sponsor or research team.

Aida MANDZO, clinical research associate

CONTACT

[email protected]

+33 (0)4 76 76 68 16

Cordélia SALOMEZ-IHL, pharmacist

CONTACT

[email protected]

+ 33 (0)4 76 76 85 27

Sponsors and collaborators

Lead sponsor

University Hospital, Grenoble

Other

Registry information

Acronym: TAURO-USE2

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Dec 2, 2025
Registry last updated
Dec 2, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.